{
 "name": "仁新",
 "slug": "tw-6696",
 "aliases": [
  "仁新醫藥股份有限公司",
  "LBS",
  "6696"
 ],
 "ticker": "6696",
 "industry": "生技醫療業",
 "website": "http://www.linbioscience.com/tw/",
 "summary": "仁新（6696）是興櫃的生技醫療類股公司，2016 年成立，2018 年登錄興櫃。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "仁新醫藥股份有限公司",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "英文簡稱",
   "value": "LBS",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "掛牌市場",
   "value": "證券櫃檯買賣中心興櫃",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "登錄興櫃日期",
   "value": "2018-10-08",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "成立日期",
   "value": "2016-05-12",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "董事長",
   "value": "林雨新",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "總經理",
   "value": "王正琪",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "實收資本額",
   "value": 835060000,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "勤業眾信聯合會計師事務所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "公司網址",
   "value": "http://www.linbioscience.com/tw/",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "管線：LBS-008（tinlarebant）",
   "value": "斯特格病變（STGD1）｜NDA獲FDA受理並獲優先審查｜美國",
   "unit": "",
   "as_of": "2026-08-12",
   "source": "https://www.linbioscience.com/TW/IM/NewsDetail/91",
   "note": "NCT05244304（DRAGON）；由仁新子公司Belite Bio開發；受理不等於核准。"
  },
  {
   "claim": "催化劑：LBS-008",
   "value": "FDA PDUFA目標審查日｜2027-02-12｜已公告",
   "unit": "",
   "as_of": "2026-08-12",
   "source": "https://www.linbioscience.com/TW/IM/NewsDetail/91",
   "note": "由公司公告轉述FDA目標日；非保證核准日。"
  },
  {
   "claim": "管線：LBS-008（tinlarebant）",
   "value": "斯特格病變（STGD1）｜已提交NDA、啟動藥品審查程序｜日本",
   "unit": "",
   "as_of": "2026-09-07",
   "source": "https://www.linbioscience.com/TW/IM/NewsDetail/92",
   "note": "由子公司Belite Bio提交；不是取得日本藥證。"
  },
  {
   "claim": "管線：LBS-008（tinlarebant）",
   "value": "斯特格病變（STGD1）｜已透過Access Consortium提交上市許可申請（MAA）｜新加坡、英國、瑞士",
   "unit": "",
   "as_of": "2026-10-15",
   "source": "https://www.linbioscience.com/TW/IM/NewsDetail/93",
   "note": "由子公司Belite Bio提交；未稱MAA已核准。"
  },
  {
   "claim": "管線：LBS-007",
   "value": "復發或難治性急性白血病｜第I/II期、招募中｜美國、澳洲、中國、台灣",
   "unit": "",
   "as_of": "2026-03-27",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT05756322",
   "note": "NCT05756322；ClinicalTrials.gov最後公開更新 2026-03-27；登錄狀態 RECRUITING。"
  },
  {
   "claim": "催化劑：LBS-007",
   "value": "NCT05756322主要完成日（登錄估計）｜2026-12-31（公司登錄預估）｜已公告",
   "unit": "",
   "as_of": "2026-03-27",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT05756322",
   "note": "NCT05756322；由試驗主辦方登錄的Estimated Primary Completion Date，並非解盲、核准或已完成。"
  },
  {
   "claim": "管線：LBS-008（tinlarebant）",
   "value": "地理性萎縮（DRAGON II以外的PHOENIX第III期試驗）｜第III期、活躍但不再招募｜美國、澳洲、歐洲等多國",
   "unit": "",
   "as_of": "2026-01-07",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT05949593",
   "note": "NCT05949593；ClinicalTrials.gov最後公開更新 2026-01-07；登錄狀態 ACTIVE_NOT_RECRUITING。"
  },
  {
   "claim": "催化劑：LBS-008",
   "value": "NCT05949593主要完成日（登錄估計）｜2027-06-30（公司登錄預估）｜已公告",
   "unit": "",
   "as_of": "2026-01-07",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT05949593",
   "note": "NCT05949593；由試驗主辦方登錄的Estimated Primary Completion Date，並非解盲、核准或已完成。"
  },
  {
   "claim": "管線：LBS-008（tinlarebant）",
   "value": "斯特格病變（DRAGON II）｜第II/III期、活躍但不再招募｜美國、日本、英國",
   "unit": "",
   "as_of": "2026-03-12",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT06388083",
   "note": "NCT06388083；ClinicalTrials.gov最後公開更新 2026-03-12；登錄狀態 ACTIVE_NOT_RECRUITING。"
  },
  {
   "claim": "催化劑：LBS-008",
   "value": "NCT06388083主要完成日（登錄估計）｜2028-02（公司登錄預估）｜已公告",
   "unit": "",
   "as_of": "2026-03-12",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT06388083",
   "note": "NCT06388083；由試驗主辦方登錄的Estimated Primary Completion Date，並非解盲、核准或已完成。"
  }
 ],
 "responses": [],
 "provided_by": "public_sources",
 "verified_by": "Drugnews｜藥時事",
 "verified_at": "2026-10-22",
 "disclosure": "Drugnews 依公開來源（公司公告、公開資訊觀測站、試驗登錄、主管機關文件）整理，於 verified_at 逐條核對來源；未經公司審閱。",
 "url": "https://drugnews.com.tw/companies/tw-6696.json",
 "generated_at": "2026-10-23T11:48:56.615Z"
}